Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism
| العنوان: | Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism |
|---|---|
| المؤلفون: | Kazuaki Fujii, Yuuta Hara, Yuji Kamijo, Taiki Okumura, Koji Hashimoto, Kosuke Sonoda, Daiki Aomura, Yukihumi Kurasawa, Yohei Ogawa, Tomoe Masuda, Akinori Yamaguchi |
| المصدر: | Internal Medicine |
| بيانات النشر: | Japanese Society of Internal Medicine, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, primary hypothyroidism, Thrombotic thrombocytopenic purpura, ADAMTS13 Protein, Case Report, 030204 cardiovascular system & hematology, Asymptomatic, Gastroenterology, 03 medical and health sciences, rituximab, 0302 clinical medicine, Hypothyroidism, hemic and lymphatic diseases, Internal medicine, Internal Medicine, medicine, Humans, Immunologic Factors, thrombotic thrombocytopenic purpura, Acquired Thrombotic Thrombocytopenic Purpura, Plasma Exchange, Purpura, Thrombotic Thrombocytopenic, business.industry, Primary hypothyroidism, General Medicine, Middle Aged, medicine.disease, ADAMTS13, Sjogren's Syndrome, Corticosteroid therapy, Sjögren's syndrome, 030211 gastroenterology & hepatology, Rituximab, medicine.symptom, Sjogren s, business, medicine.drug |
| الوصف: | A 47-year-old man was admitted to our hospital because of thrombocytopenia and consciousness disturbance. As his laboratory data showed undetectable activity of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) and the presence of ADAMTS13 inhibitor, he was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). Asymptomatic primary Sjögren's syndrome (SS) and primary hypothyroidism were incidentally diagnosed on screening. After initial plasma exchange therapy and pulse corticosteroid therapy, the patient received rituximab therapy for refractory TTP with "inhibitor boosting" and recovered. TTP secondary to primary SS is rare but can trigger refractory TTP. Treatment with rituximab, which is considered "inhibitor boosting," should be considered when re-exacerbation occurs. |
| تدمد: | 1349-7235 0918-2918 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd3fabd24ce3c6581482abc53fd454c1Test https://doi.org/10.2169/internalmedicine.3722-19Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bd3fabd24ce3c6581482abc53fd454c1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497235 09182918 |
|---|